Although HER2-targeted monoclonal antibody drugs have been adopted widely as the targeted therapy for HER2-positive BC, this treatment strategy failed to show significantly therapeutic effect on HER2-positive GC8. The gene discussed is ERBB2; the disease is breast cancer.